Search Results - "Carlsson, Conny"

Abstract 5030: The impact of ABCB1 single nucleotide polymorphisms on the outcome in lenalidomide treated multiple myeloma patients by Falk, Ingrid Jakobsen, Lund, Johan, Gréen, Henrik, Gruber, Astrid, Alici, Evren, Lauri, Birgitta, Blimark, Cecilie, Mellqvist, Ulf-Henrik, Swedin, Agneta, Forsberg, Karin, Carlsson, Conny, Hardling, Mats, Ahlberg, Lucia, Nahi, Hareth, Lotfi, Kourosh

“…Abstract Introduction: Multiple myeloma (MM) is an incurable plasma cell malignancy with high mortality rate. Treatment outcomes have improved since the…”
Get full text

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial by Jakobsen Falk, Ingrid, Lund, Johan, Gréen, Henrik, Gruber, Astrid, Alici, Evren, Lauri, Birgitta, Blimark, Cecilie, Mellqvist, Ulf-Henrik, Swedin, Agneta, Forsberg, Karin, Carlsson, Conny, Hardling, Mats, Ahlberg, Lucia, Lotfi, Kourosh, Nahi, Hareth

“…Purpose Despite therapeutic advances, patients with multiple myeloma (MM) continue to experience disease relapse and treatment resistance. The gene ABCB1…”
Get full text

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex by Lund, Johan, Karstorp, Sigrid, Alici, Evren, Gruber, Astrid, Lauri, Birgitta, Blimark, Cecilie, Swedin, Agneta, Hansson, Markus, Forsberg, Karin, Ahlberg, Lucia, Conny, Carlsson, Waage, Anders, Gimsing, Peter, Vangsted, Annette Juul, Frølund, Ulf Christian, Hardling, Mats, Mellqvist, Ulf-Henrik, Nahi, Hareth

“…Background The indication for use of lenalidomide in second line of therapy has been based upon two phase III studies comparing lenalidomide and dexamethasone…”
Get full text

Lenalidomide versus lenalidomide plus dexamethasone prolonged treatment after second-line lenalidomide plus dexamethasone induction in multiple myeloma by Lund, Johan, Gruber, Astrid, Lauri, Birgitta, Duru, Adil Doganay, Blimark, Cecilie, Swedin, Agneta, Hansson, Markus, Forsberg, Karin, Ahlberg, Lucia, Carlsson, Conny, Waage, Anders, Gimsing, Peter, Vangsted, Annette Juul, Frolund, Ulf, Holmberg, Erik, Gahrton, Gösta, Alici, Evren, Hardling, Mats, Mellqvist, Ulf-Henrik, Nahi, Hareth

“…Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single-agent…”
Get full text

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma by Lund, Johan, Gruber, Astrid, Lauri, Birgitta, Duru, Adil Doganay, Blimark, Cecilie, Swedin, Agneta, Hansson, Markus, Forsberg, Karin, Ahlberg, Lucia, Carlsson, Conny, Waage, Anders, Gimsing, Peter, Vangsted, Annette Juul, Frølund, Ulf, Holmberg, Erik, Gahrton, Gösta, Alici, Evren, Hardling, Mats, Mellqvist, Ulf‐Henrik, Nahi, Hareth

“…Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single‐agent…”
Get full text